Carnitine palmitoyltransferase II deficiency - Successful anaplerotic diet therapy

Institute of Metabolic Disease, Baylor University Medical Center, 3812 Elm St., Dallas, TX 75226, USA.
Neurology (Impact Factor: 8.29). 07/2008; 71(4):260-4. DOI: 10.1212/01.wnl.0000318283.42961.e9
Source: PubMed


Carnitine palmitoyltransferase II (CPT II) deficiency is an important cause of recurrent rhabdomyolysis in children and adults. Current treatment includes dietary fat restriction, with increased carbohydrate intake and exercise restriction to avoid muscle pain and rhabdomyolysis.
CPT II enzyme assay, DNA mutation analysis, quantitative analysis of acylcarnitines in blood and cultured fibroblasts, urinary organic acids, the standardized 36-item Short-Form Health Status survey (SF-36) version 2, and bioelectric impedance for body fat composition. Diet treatment with triheptanoin at 30% to 35% of total daily caloric intake was used for all patients.
Seven patients with CPT II deficiency were studied from 7 to 61 months on the triheptanoin (anaplerotic) diet. Five had previous episodes of rhabdomyolysis requiring hospitalizations and muscle pain on exertion prior to the diet (two younger patients had not had rhabdomyolysis). While on the diet, only two patients experienced mild muscle pain with exercise. During short periods of noncompliance, two patients experienced rhabdomyolysis with exercise. None experienced rhabdomyolysis or hospitalizations while on the diet. All patients returned to normal physical activities including strenuous sports. Exercise restriction was eliminated. Previously abnormal SF-36 physical composite scores returned to normal levels that persisted for the duration of the therapy in all five symptomatic patients.
The triheptanoin diet seems to be an effective therapy for adult-onset carnitine palmitoyltransferase II deficiency.

1 Follower
65 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A two-layered network model which learns and performs two-joint arm reaching movements in 3-D space and is consistent with neurobiological data on cell activities recorded in the motor cortex during these movements is proposed. These experimental results show that: (1) neurons which command muscle synergies are broadly tuned to preferred directions in the 3-D space, (2) the cell's preferred direction rotates with the initial position of the arm, and (3) the rotation of the arm in space and the rotation of the whole population of preferred directions are highly correlated. The motor cortex is thus working in an arm centered coordinate system, and the available visual information about the desired trajectory should be translated in this coordinate system for the appropriate command of the arm. The authors show how this computation can be performed by processing units which model the properties of the cortical column as the basic neuronal circuits common to all cortical areas
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several mouse models for mitochondrial fatty acid beta-oxidation (FAO) defects have been developed. So far, these models have contributed little to our current understanding of the pathophysiology. The objective of this study was to explore differences between murine and human FAO. Using a combination of analytical, biochemical and molecular methods, we compared fibroblasts of long chain acyl-CoA dehydrogenase knockout (LCAD(-/-)), very long chain acyl-CoA dehydrogenase knockout (VLCAD(-/-)) and wild type mice with fibroblasts of VLCAD-deficient patients and human controls. We show that in mice, LCAD and VLCAD have overlapping and distinct roles in FAO. The absence of VLCAD is apparently fully compensated, whereas LCAD deficiency is not. LCAD plays an essential role in the oxidation of unsaturated fatty acids such as oleic acid, but seems redundant in the oxidation of saturated fatty acids. In strong contrast, LCAD is neither detectable at the mRNA level nor at the protein level in men, making VLCAD indispensable in FAO. Our findings open new avenues to employ the existing mouse models to study the pathophysiology of human FAO defects.
    Biochimica et Biophysica Acta 06/2009; 1791(8):806-15. DOI:10.1016/j.bbalip.2009.05.006 · 4.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rhabdomyolysis is a common clinical syndrome and accounts for 7% of all cases of acute kidney injury (AKI) in the USA. It can result from a wide variety of disorders, such as trauma, exercise, medications and infection, but in the pediatric population, infection and inherited disorders are the most common causes of rhabdomyolysis. Approximately half of patients with rhabdomyolysis present with the triad of myalgias, weakness and dark urine. The clinical suspicion, especially in the setting of trauma or drugs, is supported by elevated creatinine kinase levels and confirmed by the measurement of myoglobin levels in serum or urine. Muscle biopsy and genetic testing should be performed if rhabdomyolysis is recurrent or metabolic myopathy is suspected. Early recognition is important to prevent AKI through the use of aggressive hydration. Prevention is important in patients with inherited forms, but novel therapies may be developed with the better understanding of the pathophysiology and genetics of rhabdomyolysis.
    Pediatric Nephrology 07/2009; 25(1):7-18. DOI:10.1007/s00467-009-1223-9 · 2.86 Impact Factor
Show more


65 Reads
Available from